Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

By            

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 17-26

Spandidos Publications

Access to resources Recommend Favorite

Second-line chemotherapy in patients with primary unknown cancer

By Ono Makiko   Ando Masashi   Yonemori Kan   Yamamoto Harukaze   Hirata Taizo   Shimizu Chikako   Tamura Kenji   Katsumata Noriyuki   Fujiwara Yasuhiro  

Journal of Cancer Research and Clinical Oncology, Vol. 137, Iss. 8, 2011-08 ,pp. : 1185-1191

Springer Publishing Company

Access to resources Recommend Favorite

Second-line chemotherapy for advanced gastric cancer in Korea

By Baek Sun   Kim Si-Young   Jeong Jae-heon   Cho Kyung   Yoon Hwi-Joong  

Gastric Cancer, Vol. 15, Iss. 4, 2012-10 ,pp. : 345-354

Springer Publishing Company

Access to resources Recommend Favorite

Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer

By Schwartzberg Lee   Cobb Patrick   Walker Mark   Stepanski Edward   Houts Arthur  

Supportive Care in Cancer, Vol. 17, Iss. 8, 2009-08 ,pp. : 1081-1088

Springer Publishing Company

Access to resources Recommend Favorite